Allurion Technologies Secures $5M in New Funding

An update from Allurion Technologies ( (ALUR) ) is now available.

On November 11, 2025, Allurion Technologies entered into a securities purchase agreement to sell shares and warrants for approximately $5 million, aiming to strengthen its balance sheet. Concurrently, the company agreed to exchange outstanding debt for convertible preferred equity with RTW Investments, which will allow RTW to convert debt into Series B Preferred Stock, enhancing Allurion’s financial position. These strategic financial maneuvers are part of Allurion’s broader efforts to secure FDA approval for its products and position itself for long-term success in the weight-loss industry.

The most recent analyst rating on (ALUR) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.

Spark’s Take on ALUR Stock

According to Spark, TipRanks’ AI Analyst, ALUR is a Underperform.

Allurion Technologies’ overall stock score is primarily impacted by its poor financial performance and valuation, with technical analysis also reflecting bearish trends. While the earnings call suggests potential future improvements, the current financial state and market conditions present significant risks.

To see Spark’s full report on ALUR stock, click here.

More about Allurion Technologies

Allurion Technologies, Inc. is a pioneer in metabolically healthy weight loss, primarily known for its Allurion Program, which includes the Allurion Smart Capsule—a swallowable, procedureless gastric balloon for weight loss—and the Allurion Virtual Care Suite. The company focuses on providing weight-loss solutions and is involved in the development of drug-eluting intragastric devices.

Average Trading Volume: 163,851

Technical Sentiment Signal: Sell

Current Market Cap: $13.51M

See more insights into ALUR stock on TipRanks’ Stock Analysis page.